Lucianne Groenink

Lucianne Groenink is associate professor, principal investigator at the Utrecht Institute for Pharmaceutical Sciences (UIPS) and affiliated partner of the Brain Center Rudolf Magnus (UMC Utrecht, The Netherlands). She is a registered Pharmacologist (Dutch Pharmacology Society), fellow member of the European College of Neuropsychopharmacology, one of the editors of the European Journal of Pharmacology and Ambassador of the Systematic Review Centre for Laboratory animal Experimentation.

Research

Lucianne has an independent research group that studies brain mechanisms that contribute to the development of stress-related disorders. The projects she has acquired and supervised focus on translational aspects of anxiety, depression and psychosis. With her preclinical experimental animal studies, she contributes to the development and validation of drug targets for the treatment of psychiatric disorders, in close collaboration with academic and industrial partners. Her pharmacological and genetic studies have resulted in over 80 peer-reviewed publications (including high impact journals) and ten PhD theses so far. More recently she has shifted her research towards the influence of the immune system on neurodevelopment. Besides her experimental studies, Groenink is engaged in several initiatives to enhance the impact of preclinical in vivo research. To this end, her group also performs systematic reviews and meta-analyses of experimental animal studies to improve the study methodology and predictive value of tests, and to identify potential drug targets.

Selected publications

  1. Bijlsma EY, Hendriksen H, Baas JM, Millan MJ, Groenink L. (2015) Lifelong disturbance of serotonin transporter functioning results in fear learning deficits: Reversal by blockade of CRF1 receptors. Eur Neuropsychopharmacol. 25(10):1733-43. doi: 10.1016/j.euroneuro.2015.07.004. 
  2. Douma TN, Millan MJ, Verdouw PM, Oosting RS, Olivier B, Groenink L. Valproate improves prepulse inhibition deficits induced by corticotropin-releasing factor independent of GABA(A) and GABA(B) receptor activation. Neuropharmacology. 2014 Apr;79:66-74. doi: 10.1016/j.neuropharm.2013.10.032. 
  3. Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, Svenningsson P, Brocco M, Gobert A, De Groote L, Cistarelli L, Veiga S, De Montrion C, Rodriguez M, Galizzi JP, Lockhart BP, Cogé F, Boutin JA, Vayer P, Verdouw PM, Groenink L, Millan MJ. Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA).J Neurosci. 2011 Nov 23;31(47):16928-40. doi: 10.1523/jneuroscience.2502-11.2011 

More information can be found on her staff page